Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15686MR)

This product GTTS-WQ15686MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Macular edema following Central Retinal Vein Occlusion (CRVO), Diabetic retinopathy research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15686MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15676MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA VB6-845
GTTS-WQ2607MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 557
GTTS-WQ9000MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMA-638
GTTS-WQ8292MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HM-12525A
GTTS-WQ10779MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA M-70
GTTS-WQ15279MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Theraloc
GTTS-WQ14217MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RG4934
GTTS-WQ14050MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA aLAG367
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW